Biology subjects

Firestone, A. J.

Publications and source records attributed to Firestone, A. J..

4 recordsLinked to original sources

bioRxiv2026

Dependencies in heterogeneous, lineage plastic patient-derived prostate cancer organoids revealed through integrated single-cell multiomics and CRISPR screening

Lineage plasticity and tumor heterogeneity limit the effectiveness of targeted therapies, yet the functional dependencies used to nominate therapeutic targets are often derived from homogeneous systems that fail to capture this complexity. Here, we establish a framework to resolve state-specific genetic vulnerabilities by integrating single-cell multiomics (RNA and ATAC) with pooled CRISPR-Cas9 screening across a large panel of patient-derived organoids (PDOs) from castrate-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC). We generate a single-cell multiome atlas spanning >190,000 cells across 22 PDOs, defining seven lineage states--including intermediate and plastic populations not resolved by bulk profiling--and demonstrate that these lineage programs robustly classify independent transcriptomic datasets from prostate cancer patient tumors. By systematically coupling this atlas to subtype-resolved CRISPR screens, we construct a functional dependency map linking cell state in heterogeneous 3D human tumor models. We show that intratumoral heterogeneity fundamentally reshapes the interpretation of gene essentiality, whereby gene-level depletion reflects the composite behavior of co-existing subpopulations, and identify a general principle in which resistant "limiting" populations disproportionately determine aggregate fitness effects. This framework reveals both canonical and previously unrecognized lineage-restricted dependencies within highly plastic tumor and NEPC states, including a therapeutically targetable dependency on the aryl hydrocarbon receptor (AHR) in a novel hybrid stem-like/ASCL1 population. Together, these data establish an extensive multi-dimensional prostate cancer resource, identify novel lineage-resolved biology, and provide a generalizable strategy for interpreting functional genomics in heterogeneous human tumors.

cancer biology↗

bioRxiv2026

MAJEC: unified gene, isoform, and locus-level transposable element quantification from RNA-seq

BackgroundThe study of transposable elements (TEs) has become increasingly central to fields such as cancer biology, immunology, and aging. Accurately quantifying disease- or laboratory-mediated perturbations in these elements is critical to support this expanding research, yet current RNA-seq pipelines struggle with the pervasive overlap between TEs and protein-coding genes. Existing tools either aggregate to the subfamily level with no locus resolution (TEtranscripts), or provide locus-level quantification without modeling gene overlap (Telescope), with the latter attributing over 40% of TE signal to the 1.1% of loci that overlap gene exons. ResultsWe present MAJEC (Momentum Accelerated Junction Enhanced Counting), a unified Expectation-Maximization (EM) framework that jointly quantifies genes, transcript isoforms, and individual TE loci from BAM alignments in a single pass. Splice junction evidence informs transcript-level priors, enabling MAJEC to probabilistically distinguish genic from TE-derived reads. This approach was independently validated against Salmon and RSEM on isoform quantification benchmarks. The joint feature space reduces exon-overlap contamination of locus-level TE estimates from 43% of total signal (Telescope) to 5% (MAJEC), while preserving subfamily-level accuracy (differential expression r = 0.987 vs TEtranscripts). Using paired biological vignettes, we demonstrate that MAJEC correctly resolves both the false TE reactivation artifacts endemic to TE-only models, and the false gene upregulation artifacts that occur when heuristic rules misassign genuine intragenic TE transcription. ConclusionMAJEC simultaneously produces the isoform and locus-level resolution that TEtranscripts lacks, with greater accuracy than Telescope, and runs faster than either.

bioinformatics↗

bioRxiv2020

ABHD17 enzymes regulate dynamic plasma membrane palmitoylation and N-Ras-dependent cancer growth

A subset of Ras proteins, including N-Ras, depend on a palmitoylation/depalmitoylation cycle to regulate their subcellular trafficking and oncogenicity. General lipase inhibitors such as Palmostatin M block N-Ras depalmitoylation, but lack specificity and target several enzymes displaying depalmitoylase activity. Here, we describe ABD957, a potent and selective covalent inhibitor of the ABHD17 family of depalmitoylases, and show that this compound impairs N-Ras depalmitoylation in human acute myeloid leukemia (AML) cells. ABD957 produced partial effects on N-Ras palmitoylation compared to Palmostatin M, but was much more selective across the proteome, reflecting a plasma membrane-delineated action on dynamically palmitoylated proteins. Finally, ABD957 impaired N-Ras signaling and the growth of NRAS-mutant AML cells in a manner that synergizes with MEK inhibition. Our findings uncover a surprisingly restricted role for ABHD17 enzymes in modulating the N-Ras palmitoylation cycle and suggest that ABHD17 inhibitors may have value as targeted therapies for NRAS-mutant cancers.

cancer biology↗

bioRxiv2019

Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance

Only a subset of cancer patients respond to T-cell checkpoint inhibitors, highlighting the need for alternative immunotherapeutics. We performed CRISPR-Cas9 screens in a leukemia cell line to identify perturbations that enhance natural killer effector functions. Our screens defined critical components of the tumor-immune synapse and highlighted the importance of cancer cell interferon-{gamma} signaling in modulating NK activity. Surprisingly, disrupting the ubiquitin ligase substrate adaptor DCAF15 strongly sensitized cancer cells to NK-mediated clearance. DCAF15 disruption induced an inflamed state in leukemic cells, including increased expression of lymphocyte costimulatory molecules. Proteomic and biochemical analysis revealed that cohesin complex members were endogenous client substrates of DCAF15. Genetic disruption of DCAF15 was phenocopied by treatment with indisulam, an anticancer drug that functions through DCAF15 engagement. In AML patients, reduced DCAF15 expression was associated with improved survival. These findings suggest that DCAF15 inhibition may have useful immunomodulatory properties in the treatment of myeloid neoplasms.

cancer biology↗